Navigation Links
Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
Date:12/8/2009

MEDIA, Pa., Dec. 8 /PRNewswire/ -- Shepherd, Finkelman, Miller & Shah, LLP (Link';s.eVar3=s.prop5;s.prop15='78802152';s.tl(this,'o','ExternalLink');">http://www.sfmslaw.com; e-mail: Link';s.eVar3=s.prop5;s.prop15='78802152';s.tl(this,'o','ExternalLink');">jmiller@sfmslaw.com), a law firm with offices in California, Connecticut, Florida, New Jersey, Pennsylvania and Wisconsin, has filed a lawsuit seeking class action status in the United States District Court for the Eastern District of Pennsylvania against Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") (Amex: HEB) and the Company's CEO, William A. Carter, M.D., on behalf of all purchasers of Hemispherx securities between February 18, 2009 and November 2, 2009, inclusive (the "Class Period"). A copy of the Complaint filed in this action can be obtained from the Court, or you can call our offices toll free at either 866/540-5505 or 877/891-9880 to speak with an attorney regarding this matter and we will send you a copy of the Complaint.

The Complaint alleges that the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder. Specifically, the Complaint alleges that, throughout the Class Period, the Company issued a series of materially false and misleading statements to the market concerning the status of its application for approval by the U.S. Food and Drug Administration ("FDA") of Ampligen, its experimental drug for the treatment of Chronic Fatigue Syndrome. While the market understood that the Company's application was complete and that any delays in FDA action were due to constraints on the FDA's resources, the Company took advantage of the inflated stock price to, among other things, raise millions of dollars in two public stock offerings.

On November 2, 2009, the Company announced that it still needed to submit additional information to the FDA, and revealed that it had already submitted six previously undisclosed reports to the FDA. As noted by market observers, this news stood in stark contrast to Class Period statements regarding the supposed status of Hemispherx's New Drug Application ("NDA"). As a result of this revelation, shares of Hemispherx's common stock closed at $1.33 per share on November 2, 2009, down $0.12 per share, and fell even more precipitously the next day, closing at $1.13 per share, well below the Class Period high of $3.75 per share reached on June 4, 2009. On December 1, 2009, Hemispherx announced that its NDA had been rejected by the FDA.

If you purchased Hemispherx securities between February 18, 2009 and November 2, 2009 (inclusive), you may qualify to serve as lead plaintiff on behalf of the Class. All motions for appointment as a lead plaintiff must be filed with the Court by no later than January 11, 2010. Any member of the proposed Class may move the Court to serve as lead plaintiff in this action through counsel of their choice, or may remain an absent Class member. There are certain legal requirements to serve as lead plaintiff, which we would be pleased to discuss with you. Please contact James E. Miller, Esquire (866/540-5505; Link';s.eVar3=s.prop5;s.prop15='78802152';s.tl(this,'o','ExternalLink');">jmiller@sfmslaw.com) or James C. Shah, Esquire (877/891-9880; Link';s.eVar3=s.prop5;s.prop15='78802152';s.tl(this,'o','ExternalLink');">jshah@sfmslaw.com), if you would like to discuss this action or have any question regarding this notice or your rights.

Shepherd, Finkelman, Miller & Shah, LLP (Link';s.eVar3=s.prop5;s.prop15='78802152';s.tl(this,'o','ExternalLink');">http://www.sfmslaw.com) is a law firm that represents investors, including institutions and individuals, as well as consumers, in class action and other complex litigation, and maintains offices in California, Connecticut, Florida, New Jersey, Pennsylvania and Wisconsin. The firm's attorneys have appeared in matters on behalf of our clients throughout the United States and have been appointed lead counsel in a number of class actions and corporate governance matters.

SOURCE Shepherd, Finkelman, Miller & Shah, LLP


'/>"/>
SOURCE Shepherd, Finkelman, Miller & Shah, LLP
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. MICROS to Present at Wachovia Securities 1st Annual Services Conference
2. AHPC Holdings, Inc. Announces Intent to Deregister Common Stock With Securities and Exchange
3. Stryker Discloses Informal Inquiry Made by United States Securities and Exchange Commission
4. RxElite Files Registration Statement with Securities and Exchange Commission
5. Summary Notice of Class Action in Re McKesson HBOC, Inc. Securities Litigation
6. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
7. Genomic Health to Present at JMP Securities Healthcare Focus Conference
8. Wolf Popper Announces Filing of Securities Class Action Lawsuit Against Medtronic Inc. - MDT
9. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
10. American Stock Exchange LLC to Delist Securities of AMS Health Sciences, Inc.
11. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Sector Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
Breaking Medicine Technology: